Share

October 2021; 11 (5) ResearchOpen Access

Epilepsy Treatment Complacency in Patients, Caregivers, and Health Care Professionals

Patricia E. Penovich, John M. Stern, Danielle A. Becker, Lucretia Long, Nancy Santilli, Lynanne McGuire, Eugenia Y. Peck
First published March 9, 2021, DOI: https://doi.org/10.1212/CPJ.0000000000001066
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
598

Share

Article Information

vol. 11 no. 5 377-384
DOI: 
https://doi.org/10.1212/CPJ.0000000000001066
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received October 13, 2020
  • Accepted January 27, 2021
  • First Published March 9, 2021.

Article Versions

Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Patricia E. Penovich, MD*,
    2. John M. Stern, MD*,
    3. Danielle A. Becker, MD,
    4. Lucretia Long, APRN-CNP,
    5. Nancy Santilli, PNP, MN,
    6. Lynanne McGuire, PhD and
    7. Eugenia Y. Peck, PhD
  1. Patricia E. Penovich, MD*,
    2. Scientific Advisory Boards:

    1. Commercial: GW Pharma Commercial: UCB Pharmaceutical Company Commercial: SK Life Sciences Commercial: Neurelis Commercial: Engage Therapeuetics

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Please note this is the same as Speaker's Bureau below: Commercial: GW Pharma Commercial: SK Life Science UCB Pharmaceuticals: Commercial:

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Commercial: GW Pharmaceuticals Commercial: SK Life Sciences Commercial: UCB Pharma Commercial: Eisai

    Other activities:

    1. Professional Advisory Board: Epilepsy Foundation of America Professional Advisory Board: Epilepsy Foundation Minnesota

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH: Monead Study - study budget funds went to my employer, I received no personal compensation for the work Epilepsy Consortium - Study Funds went to my employer for stduy expenses

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1. Tuberous Sclerosis Alliance - funds went to my employer for study budget expenses

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. John M. Stern, MD*,
    3. Scientific Advisory Boards:

    1. UCB, SK Life Sciences, Neurelis, Eisai,

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. MedScape

    Editorial Boards:

    1. MedLink Neurology, Assoc. Editor, 2008-2018 International Journal of Epilepsy, Ed Board, 2013-2018

    Patents:

    1. NONE

    Publishing Royalties:

    1. Atlas of EEG Patterns 2nd ed, Lippincott Williams & Wilkins, 2013 Atlas of Video-EEG Monitoring, McGraw-Hill, 2011 Medication Resistant Epilepsy, 2020

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. UCB, Sunovion, Eisai, Lundbeck, Neurelis, Greenwich, SK Life Sciences

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. Clinical epilepsy, UCLA, 50% of effort

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Leff Family Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Danielle A. Becker, MD,
    4. Scientific Advisory Boards:

    1. (1) SK life Science advisory board (2) Neurelis advisory board (3) Supernus advisory board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. (1) SK life Science advisory board (2) Neurelis advisory board (3) Supernus advisory board

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Lucretia Long, APRN-CNP,
    5. Scientific Advisory Boards:

    1. SK Life pharmaceutical Novartis Pharmaceutical Eisai Pharmaceutical Neurelis Incorporated

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Liva Nova

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Nancy Santilli, PNP, MN,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1. SK Life Sciences 2. Neurelis Pharmaceuticals

    Speakers' Bureaus:

    1. SK Life Sciences

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Lynanne McGuire, PhD and
    7. Scientific Advisory Boards:

    1. I am an employee of MedVal Scientific Information Services, which was contracted by SK Life Science, Inc for medical writing services.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Eugenia Y. Peck, PhD
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Kantar, inc. VP Research, 12 years

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Minnesota Epilepsy Group (PEP), Saint Paul; Department of Neurology (JMS), University of California at Los Angeles; Penn Epilepsy Center (DAB), Hospital of the University of Pennsylvania, Philadelphia; Department of Neurology (LL), The Ohio State University Medical Center, Columbus; Human Care Systems Inc. (NS), San Francisco, CA; MedVal Scientific Information Services (LM), Princeton, NJ; and Health Division (EYP), Kantar Health, New York, NY.
  1. Correspondence
    Dr. Penovich ppenovich{at}mnepilepsy.net
View Full Text

Article usage

Article usage: March 2021 to February 2023

AbstractFullPdfSource
Mar 2021181041Highwire
Apr 202177031Highwire
May 202125023Highwire
Jun 202140014Highwire
Jul 202127014Highwire
Aug 202124019Highwire
Sep 202142021Highwire
Oct 20213358288Highwire
Nov 20211116379Highwire
Dec 2021129540Highwire
Jan 202205719Highwire
Feb 2022410315Highwire
Mar 2022210719Highwire
Apr 202215313Highwire
May 202233917Highwire
Jun 202213619Highwire
Jul 20220319Highwire
Aug 202213616Highwire
Sep 202246830Highwire
Oct 202233518Highwire
Nov 202268120Highwire
Dec 202252910Highwire
Jan 202323614Highwire
Feb 20231349Highwire

Cited By...

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me